Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (HK:9989) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
At Shenzhen Hepalink Pharmaceutical Group Co., Ltd.’s Annual General Meeting, shareholders passed all proposed resolutions by a substantial majority. The resolutions included the company’s annual reports, profit distribution proposal, and strategic financial management decisions for 2023. The AGM, which featured a 60.29% shareholder attendance, confirmed the company’s plans for wealth management and bank credit facilities for the upcoming year.
For further insights into HK:9989 stock, check out TipRanks’ Stock Analysis page.